[CAS NO. 1256756-88-3] Retagliptinphosphate
PRODUCTS SPECIFICATIONS [1256756-88-3]
DESCRIPTION [1256756-88-3]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 562.36 |
| Molecular Formula | C19H21F6N4O7P |
| SMILES | O=C(C1=C2CN(C(C[C@H](N)CC3=CC(F)=C(F)C=C3F)=O)CCN2C(C(F)(F)F)=N1)OC.O=P(O)(O)O |
Summary
Retagliptin phosphate (SP2086 phosphate) is a selective, competitive and orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. Retagliptin phosphate can be used for type 2 diabetes mellitus (T2DM) research [1] .
IC50 & Target
DPP-4 [1] .
In Vitro
Retagliptin is a class of compound used for research of type 2 diabetes. Retagliptin inhibits the degradation of GLP-1, thus amplifying the incretin effect [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT05054842 | Jiangsu HengRui Medicine Co., Ltd. |
Type 2 Diabetes
|
December 6, 2021 | Phase 3 |
| NCT02815748 | Jiangsu HengRui Medicine Co., Ltd. |
Type 2 Diabetes
|
August 2015 | Phase 1 |
| NCT02817217 | Jiangsu HengRui Medicine Co., Ltd. |
Type 2 Diabetes
|
March 2016 | Phase 1 |
| NCT02815774 | Jiangsu HengRui Medicine Co., Ltd. |
Renal Insufficiency
|
June 2014 | Phase 1 |
| NCT02815657 | Jiangsu HengRui Medicine Co., Ltd. |
Type 2 Diabetes
|
April 2013 | Phase 1 |
| NCT02815787 | Jiangsu HengRui Medicine Co., Ltd. |
Type 2 Diabetes
|
March 2014 | Phase 1 |
| NCT02826044 | Jiangsu HengRui Medicine Co., Ltd. |
Type 2 Diabetes
|
July 2016 | Phase 1 |
| NCT02821871 | Jiangsu HengRui Medicine Co., Ltd. |
Type 2 Diabetes
|
March 2016 | Phase 1 |
| NCT01969357 | Jiangsu HengRui Medicine Co., Ltd. |
Type 2 Diabetes
|
June 2011 | Phase 2 |
| NCT01970033 | Jiangsu HengRui Medicine Co., Ltd. |
Type 2 Diabetes
|
December 2012 | Phase 3 |
| NCT01970046 | Jiangsu HengRui Medicine Co., Ltd. |
Type 2 Diabetes
|
April 2013 | Phase 3 |
| NCT01969318 | Jiangsu HengRui Medicine Co., Ltd. |
Type 2 Diabetes
|
March 2012 | Phase 2 |
| NCT02813863 | Jiangsu HengRui Medicine Co., Ltd. |
Type 2 Diabetes
|
December 2015 | Phase 1 |
| NCT02500485 | Jiangsu HengRui Medicine Co., Ltd. |
Type 2 Diabetes
|
May 2015 | Phase 1 |
| NCT02815722 | Jiangsu HengRui Medicine Co., Ltd. |
Type 2 Diabetes
|
July 2013 | Phase 1 |
| NCT02822534 | Jiangsu HengRui Medicine Co., Ltd. |
Type 2 Diabetes
|
April 2016 | Phase 1 |
| NCT02817243 | Jiangsu HengRui Medicine Co., Ltd. |
Type 2 Diabetes
|
March 2016 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : ≥ 150 mg/mL ( 266.73 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.7782 mL | 8.8911 mL | 17.7822 mL |
| 5 mM | 0.3556 mL | 1.7782 mL | 3.5564 mL |
| 10 mM | 0.1778 mL | 0.8891 mL | 1.7782 mL |
References
- [1] Hu C, et al. Pharmacokinetics of Phosphate Retagliptin Tabletin in Patients with Renal Dysfunction. Sichuan Da Xue Xue Bao Yi Xue Ban. 2018 Jan;49(1):74-80.
- [2] Avivit Cahn, et al. An update on DPP-4 inhibitors in the management of type 2 diabetes. Expert Opin Emerg Drugs. 2016 Dec;21(4):409-419.
